JNB: Research on the mechanism of formononetin inhibiting cervical cancer

Cervical cancer is the most common cancer among women with cancer-related deaths

Cervical cancer Cervical cancer treatment effect is still poor The treatment effect is still poor New treatment strategy New treatment strategy

At present, the PD-1/PD-L1 immune checkpoint has become a potential therapeutic target due to its regulatory effect on the immune response of a variety of cancers including cervical cancer

PD-1/PD-L1 immune checkpoint PD-1/PD-L1 immune checkpoint PD-L1 inhibitor is considered to be an effective treatment for cervical cancer PD-L1 inhibitor is considered to be an effective treatment for cervical cancer

The proto-oncogene MYC induces cell proliferation, growth and differentiation.

Proto-oncogene MYC proto-oncogene MYC MYC is an important regulator of the expression of PD-L1 MYC is an important regulator of the expression of PD-L1 activation of STAT3 increased PD-L1 expression of STAT3 activation increased PD-L1 expression formononetin Formononetin has inhibitory ability on a variety of cancer cells.

In vivo and in vitro experiments In vivo and in vitro experimental molecular docking experimental molecular docking experimental protein/RNA expression level protein/RNA expression level histopathology, immunohistochemistry, histopathology, immunohistochemistry

The results showed that formononetin inhibits the synthesis of PD-L1 protein by reducing the expression of MYC and STA T3 protein

Thorn formononetin inhibiting PD-L1 protein by decreasing the expression of MYC and STA T3 protein synthesis thorn formononetin inhibiting PD-L1 protein by decreasing the expression of MYC and STA T3 protein synthesis by TFEB and TFE3 mediated Promotes PD-L1 protein degradation through TFEB and TFE3-mediated lysosome development, promotes PD-L1 protein degradation, promotes tumor cell apoptosis, and promotes tumor cell apoptosis

The study revealed the anti-tumor effect of formononetin, and provided a basis for further research and development of anti-cancer drugs for cervical cancer

Provide a basis for further research and development of cervical cancer anticancer drugs Provide a basis for further research and development of cervical cancer anticancer drugs

 

Literature source:

Literature source:

Wang Jing Ying,Jiang Ming Wen,Li Ming Yue et al.

Wang Jing Ying,Jiang Ming Wen,Li Ming Yue et al.

Leave a message here